Thomas C. Wicka

Novu LLC develops health technology platform. It offers solutions in the areas of health programming, community management, gamification mechanics, consumer-centered communication, rewards management, technology and data integration, health screening management, daily program management, and reporting and analytics. The company was founded by James C. Wicka, Thomas C. Wicka, and John D. Wicka in 2010 and is headquartered in Minneapolis, MN.

Novu LLC develops health technology platform. It offers solutions in the areas of health programming, community management, gamification mechanics, consumer-centered communication, rewards management, technology and data integration, health screening management, daily program management, and reporting and analytics. The company was founded by James C. Wicka, Thomas C. Wicka, and John D. Wicka in 2010 and is headquartered in Minneapolis, MN.

Novu LLC develops health technology platform. It offers solutions in the areas of health programming, community management, gamification mechanics, consumer-centered communication, rewards management, technology and data integration, health screening management, daily program management, and reporting and analytics. The company was founded by James C. Wicka, Thomas C. Wicka, and John D. Wicka in 2010 and is headquartered in Minneapolis, MN.

Novu LLC develops health technology platform. It offers solutions in the areas of health programming, community management, gamification mechanics, consumer-centered communication, rewards management, technology and data integration, health screening management, daily program management, and reporting and analytics. The company was founded by James C. Wicka, Thomas C. Wicka, and John D. Wicka in 2010 and is headquartered in Minneapolis, MN.

Novu LLC develops health technology platform. It offers solutions in the areas of health programming, community management, gamification mechanics, consumer-centered communication, rewards management, technology and data integration, health screening management, daily program management, and reporting and analytics. The company was founded by James C. Wicka, Thomas C. Wicka, and John D. Wicka in 2010 and is headquartered in Minneapolis, MN.

Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka.